Praxsyn Income Statement | StatInvestor

Retail & Wholesale » Retail | Praxsyn Corp.

Praxsyn Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.

2010

2011

2012

2013

2014

2017

2018

Sales/Revenue

1,348.50

1,584.40

-

-

66,598.90

819.10

81.40

Cost of Goods Sold (COGS) incl. D&A

1,588.70

1,821.10

51.60

41.20

3,586.20

433.20

57.50

Gross Income

240.20

236.70

51.60

41.20

63,012.70

385.90

23.90

SG&A Expense

3,560.60

3,579.10

1,684.90

947.30

36,946.70

3,100.20

219.80

EBIT

3,800.80

3,815.80

1,736.50

988.50

26,066.10

2,714.40

195.90

Unusual Expense

-

3,032.10

1,709.10

4,224.30

6,886.30

200

-

Non Operating Income/Expense

-

-

427.10

-

15.80

-

-

Interest Expense

255.30

664.00

423.10

223.50

31,732.50

581.80

369.60

Pretax Income

4,055.90

7,511.90

877.60

5,436.20

12,568.50

3,496.10

565.50

Income Tax

-

1.70

1.60

0.80

214.10

-

-

Consolidated Net Income

4,055.90

7,513.60

879.20

5,437.00

12,354.40

3,496.10

565.50

Net Income

4,055.90

7,513.60

879.20

5,437.00

12,354.40

3,496.10

565.50

Net Income After Extraordinaries

4,055.90

7,513.60

539.70

5,437.00

12,354.40

3,496.10

565.50

Net Income Available to Common

4,055.90

7,513.60

1,218.80

5,437.00

12,354.40

3,496.10

565.50

EPS (Basic)

0.08

0.18

0.02

0.05

0.05

-

-

Basic Shares Outstanding

51,055.00

42,836.00

71,122.90

99,543.10

268,948.50

725,427.10

739,440.80

EPS (Diluted)

0.08

0.18

0.02

0.05

0.05

-

-

Diluted Shares Outstanding

51,055.00

42,836.00

71,122.90

99,543.10

268,948.50

725,427.10

739,440.80

EBITDA

3,775.00

3,752.70

1,684.90

947.30

26,082.00

2,684.10

138.50

Non-Operating Interest Income

0.20

-

-

-

-

-

-

About Praxsyn

View Profile

Address	61 Spectrum Boulevard Las Vegas Nevada 89101 United States
Employees	-
Website	http://www.praxsyncorp.com
Updated	07/08/2019
Praxsyn Corp. operates as a holding company, which engages in providing patients of medical practitioners with medications, and services. Through its subsidiary, it provides custom compounded non-narcotic, transdermal topical pain medications, which are marketed to industrial health physicians, and medical clinics. The company was founded by Wiesel Daniel and Alysa Binder on June 5, 2005 and is headquartered in Irvine, CA.